ContractWarrant Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES PURCHASABLE HEREUNDER HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR QUALIFICATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
COLLABORATION AND LICENSE AGREEMENT by and between KYOWA HAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013Collaboration and License Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is made effective as of August 29, 2013 (the “Effective Date”), by and between Kyowa Hakim Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“KHK”), and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of California, U.S.A., with an address at 60 Leveroni Ct. Novato, CA 94949, U.S.A. (“UGNX”). KHK and UGNX are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO LICENSE AND SERVICES AGREEMENTLicense and Services Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO LICENSE AND SERVICES AGREEMENT (herein referred to as “Amendment No. 1”) is made and entered into as of this September 4th, 2012 (the “Amendment No. 1 Effective Date”), by and between Ultragenyx Pharmaceutical, Inc. (herein referred to as “Ultragenyx”), a California Corporation, and The Buck Institute for Research on Aging, an independent non-profit research organization organized under the laws of California (“Buck”), each herein referred to individually as “Party” and collectively as “Parties”.
License and Services AgreementLicense and Services Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This License and Services Agreement (“Agreement”) is entered into on September 24, 2010 by and between The Buck Institute for Age Research, an independent non-profit research organization (“Buck”) with facilities at 8001 Redwood Blvd., Novato, CA 94945 (“Facility”) and Ultragenyx Pharmaceutical Inc., a California corporation, located at 77 Digital Drive, Suite 210, Novato, CA 94949 (“Ultragenyx”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
THIS EXCLUSIVE LICENSE AGREEMENT including the exhibits referred to herein and attached hereto which are hereby incorporated by reference (the “Agreement”), effective as of April 23, 2012 (the “Effective Date”), is made and entered into by and between the HIBM Research Group, a non-profit public benefit California corporation, having a principal place of business located at 18341 Sherman Way, #201A, Reseda, CA 91335 (“HRG”) and Ultragenyx Pharmaceutical Inc., a Delaware corporation having a principal place of business located at 60 Leveroni Ct., Novato, California (“UPI”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”), dated June 15, 2011, is between ULTRAGENYX PHARMACEUTICAL INC. (the “Company”) and EMIL D. KAKKIS, M.D., PH.D. (“Executive”).
LICENSE AGREEMENTLicense Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Delaware
This License Agreement is entered into as of the 1st day of March, 2011 (the “EFFECTIVE DATE”) between AAIPharma Services Corp., having its principal offices at 2320 Scientific Park Drive, Wilmington, North Carolina 28405 (hereinafter “AAI”), and Ultragenyx Pharmaceutical, Inc., having principal offices at 77 Digital Drive, Suite 210, Novato, California 94949 (hereinafter “ULTRAGENYX”).
SUPPLY AGREEMENT between CREMER OLEO GmbH & Co KG, Glockengiesserwall 3, 20095 Hamburg, Germany — hereinafter referred to as Cremer — and Ultragenyx Pharmaceutical Inc, 60 Leveroni Court, Suite 200, Novato, California 94949, United States of America —...Supply Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
Whereas, Ultragenyx is a biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market;
AMENDMENT LICENSE AGREEMENTLicense Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment to the License Agreement (“Amendment”) is made and entered into by and between Ultragenyx Pharmaceutical Inc., a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 60 Leveroni Court, Novato, CA 94949 (“Ultragenyx”), and Baylor Research Institute, a non-profit corporation organized and existing under the laws of the State of Texas, having its principal place of business at 3310 Live Oak Street, Suite 501, Dallas, Texas 75204 (“BRI”).
ULTRAGENYX PHARMACEUTICAL INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Dated as of December 18, 2012Investors’ Rights Agreement • October 4th, 2013 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 18, 2012 by and among Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”) and the investors listed on Schedule A hereto (each an “Investor” and collectively the “Investors”).
